Abstract: Slide Presentations |

Modafinil Adjunctive Therapy Improves Excessive Sleepiness and Functional Status in Obstructive Sleep Apnea: A 12-Month Open-Label Extension Study FREE TO VIEW

Max Hirshkowitz, MD
Author and Funding Information

VA Medical Center, Houston, TX


Chest. 2003;124(4_MeetingAbstracts):75S. doi:10.1378/chest.124.4_MeetingAbstracts.75S
Text Size: A A A
Published online


PURPOSE:  Nothwithstanding regular use of nasal continuous positive airway pressure (nCPAP), some patients with obstructive sleep apnea (OSA) experience residual excessive sleepiness. In double-blind studies, modafinil, a novel wake-promoting agent, significantly improves wakefulness in patients with OSA who regularly use nCPAP. This 12-month open-label extension study evaluated long-term treatment with modafinil for residual excessive sleepiness in patients with OSA who were using nCPAP.

METHODS:  Eligible patients from a 12-week, randomized, double-blind, placebo-controlled study were enrolled in a 12-month, open-label extension trial. Modafinil was administered at either 200 mg/day, 300 mg/day, or 400 mg/day (adjusted clinically). Efficacy assessments included the epworth sleepiness scale (ESS) every three months, and the Functional Outcomes of Sleep Questionnaire (FOSQ) at Month 12 (or final visit).

RESULTS:  266 patients entered the open-label period; 175 (66%) completed the study. Modafinil significantly improved self-reporting wakefulness (assessed by ESS), at all time points. Mean changes (±SD) in ESS scores from baseline (baseline score, 14.5±3.6) at Months 3, 6, 9, and 12 were −5.7±4.5, −5.3±4.4, −5.4±4.6, and −4.5±4.7, respectively (p<0.01). Modafinil significantly improved functional status, measured as the mean change from baseline to final visit in the total score on FOSQ (increased 14% from baseline; p<0.01). Long-term modafinil treatment was well tolerated. The most frequently reported adverse events (≥5%) were infection (11%), nervousness (9%), headache (9%), accidental injury (8%), sinusitis (7%), rhinitis (7%), depression and anxiety (6% each), and insomnia and dizziness (5% each); most were mild or moderate in severity.CONCLUSIONS: Modafinil increased self-reported wakefulness, improved functional status, and was well-tolerated during 12-months treatment in nCPAP compliant patients with OSA who experienced residual sleepiness.

CLINICAL IMPLICATIONS:  Modafinil is effective for long term use as a good adjunctive therapy to augment nCPAP to improve wakefulness and functional status in patients with OSA.

DISCLOSURE:  M. Hirshkowitz, None. Supported by Cephalon, Inc., West Chester, PA

Monday, October 27, 2003

8:00 AM - 9:30 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543